Back to search results

Isoquercetin for Ovarian Cancer and Blood Clot Risk

This study is looking at whether a drug called isoquercetin can help reduce the risk of blood clots in people with ovarian cancer. If you have ovarian cancer (epithelial, serous, or clear cell type) and are starting your first round of chemotherapy, you might be able to join. The study will compare isoquercetin to a placebo (an inactive substance) to see if it lowers certain markers in your blood related to blood clot formation. The main goal is to measure how much these markers change over about six weeks. The current status of this study is unclear, and it plans to enroll about 90 people.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 90 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at up to 6 weeks from baseline.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07303894

A Study of Isoquercetin in People With Ovarian Cancer

Recruiting
PHASE2Ages 18+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~90 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:IsoquercetinPlacebo

At a glance

Recruiting sites
7 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Level of PDI-sensitive, platelet-dependent thrombin generation measured as compared to baseline
Measured over up to 6 weeks from baseline

Conditions

Ovarian Cancer
Epithelial Ovarian Cancer
Serous Ovarian Tumor

Explore related trials

Malignant Ovarian Neoplasm

Where it's being run

8 sites across 3 states
New York4
New Jersey3
Massachusetts1

Study leadership

  • Jeffrey Zwicker, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Jeffrey Zwicker, MD
[email protected]
646-608-3723
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must have histological- or cytological-confirmed ovarian cancer (epithelial, serous, or clear cell) and be receiving first-line chemotherapy (day 1 of isoquercetin should align with day 1 of cycle 1 or 2 of chemotherapy) for neoadjuvant, adjuvant, or advanced settings.
Minimum age 18 years
Life expectancy of greater than 6 months.
ECOG performance status \<2
Participants must have preserved organ and marrow function as defined below:
Platelet count \> 50,000/mcL
Prothrombin time (PT) and partial thromboplastin time (PTT) \< 1.5 x institutional upper limit of normal (ULN)
Total bilirubin \< 3 x ULN without liver metastases and \<5 x ULN in presence of liver metastases.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 X ULN without liver metastases and \<5 x ULN in the presence of liver metastases.
Estimated creatinine clearance (CrCl \>30 ml/min)
The effects of isoquercetin on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion

Prior history of documented venous thromboembolic event within the last 2 years (excluding central line associated events whereby patients completed anticoagulation)
Active bleeding or high risk for bleeding (e.g., known acute gastrointestinal ulcer)
History of significant hemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 24 months
Familial bleeding diathesis
Known diagnosis of disseminated intravascular coagulation (DIC)
Currently receiving anticoagulant therapy
Current daily use of aspirin, clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g ibuprofen \> 800 mg daily or equivalent)
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Known intolerance of (iso)quercetin, niacin or ascorbic acid (including known G6PD deficiency).
Participants with known brain metastases
Pregnant women are excluded from this study because isoquercetin is a PDI inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with isoquercetin, breastfeeding should be discontinued if the mother is treated with isoquercetin.

What this trial measures

  • Level of PDI-sensitive, platelet-dependent thrombin generation measured as compared to baselineup to 6 weeks from baseline

    The primary endpoint is the maximal inhibition of PDI-sensitive, platelet-dependent thrombin generation measured at either 3 or 6 weeks (relative to baseline).